The rationale is that, with the virus raging alongside uncertainty about vaccine supply, vaccinating a greater number of people with a single dose would be more effective at preventing deaths and hospitalisations than if a smaller number of people received two doses. However critics question the wisdom of moving away from the timetable tested during clinical trials.
Here are five things to know about the evidence and potential implications of delaying vaccine doses.
1. There is little trial evidence to show what impact this will have on the Pfizer/BioNTech vaccine
When UK officials announced the new guidelines, two vaccines had been authorised for use.
Government officials have reportedly begun talks with hotel groups over plans
It comes after ministers asked officials to look into a quarantine hotel scheme
Similar hotel schemes are used in countries such as Australia and New Zealand
In Australia, travellers have to pay up to £1,500 to cover cost of two week stay
Hotel system could be used to help prevent spread of new Covid strains in UK
Share
Vaccines are some of the most cost-effective public health interventions, saving millions of lives each year. They offer the best chance of stemming the spread of the coronavirus which has resulted in many cases of ill-health and deaths across the globe. Public health experts say that at least 70 per cent of any community must get vaccinated against COVID-19 to achieve an acceptable level of immunity to protect its members.
Many countries are already making substantial efforts to assess and advance their readiness for COVID-19 vaccines. Success anywhere, however, hinges on whether individuals are willing to accept the vaccine and follow the correct vaccination course. Vaccine hesitancy is a delay in acceptance or refusal of vaccination despite the availability of vaccination services.
Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director
Posted On: 2021-01-21 01:36:22 (Time Zone: Arizona, USA)
Biocon Biologics Ltd., a fully integrated pure play biosimilars company and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that it has inducted Professor Peter Piot to its Board as an Independent Director. Professor Piot, MD, PhD is the Director of the London School of Hygiene & Tropical Medicine and the Handa Professor of Global Health.
Ms Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: I welcome Professor Peter Piot to the Biocon Biologics board. He brings years of scientific expertise, long experience in public health interventions and policy framing on major health issues. His thought leadership and invaluable experience in global healthcare will greatly guide our actions in building Biocon Biologics into an innovative global leader in biosimilars committed to delivering affordable